Pacific Biosciences of California Inc. Overview
Pacific Biosciences of California, Inc., a health care company based in Menlo Park, United States, operates within the Life Sciences Tools & Services sector. The company is renowned for its innovative sequencing systems, which are designed to assist scientists in resolving genetically complex problems. Utilizing Single Molecule, Real-Time (SMRT) technology, Pacific Biosciences enables real-time analysis of biomolecules with single molecule resolution, setting a high standard in the field of genomics.
Financial Snapshot
As of June 11, 2025, Pacific Biosciences’ stock closed at $1.18 on the Nasdaq exchange. The company’s market capitalization stands at approximately $300.08 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $2.72 on November 6, 2024, and a 52-week low of $0.85 on May 27, 2025. The price-to-earnings ratio is currently at -0.437501, reflecting the company’s financial performance and market conditions.
Industry Position and Offerings
Pacific Biosciences continues to be a key player in the health care sector, particularly within the niche of life sciences tools and services. The company’s focus on developing advanced sequencing technologies positions it as a critical resource for researchers tackling complex genetic challenges. For more detailed information about Pacific Biosciences and its product offerings, interested parties can visit the company’s website at www.pacb.com .
Conclusion
Pacific Biosciences of California, Inc. remains committed to advancing genomic research through its cutting-edge sequencing technologies. Despite recent stock market fluctuations, the company’s innovative approach and specialized offerings continue to support its role in the life sciences industry.